SangAsept – Revolutionizing Sepsis Care
SangAsept is a unique process that treats blood outside the body and generates an immediate effect on bacteria present in blood.
New technology set to revolutionize sepsis treatment, save lives and reduce antibiotic resistance
Sepsis affects 49 million people annually and has a high mortality rate. Treatments rely heavily on antibiotics, contributing to antibiotic resistance. Sangair has developed SangAsept, a technology that reduces E. coli and Pseudomonas in the blood and lowers inflammation, offering improved care and reducing the reliance on antibiotics.
“If SangAsept can show that it saves One life with severe Sepsis, it will be a standard equipment in every Intensive Care Unit in the world. This may become the first real alternative and innovation since the discovery of Antibiotics to treat a bacterial infection in blood.”
Press Releases
Headquarter Moves to Lund to Accelerate Development
After presenting encouraging preclinical results in January — demonstrating highly valuable clinical benefits — Sangair AB now takes the next…
New article with positive results published
New article with positive results published by the team behind Sangair! Sepsis carries a high mortality rate, and current treatments…
World Sepsis Day 2025
On September 13th, the global spotlight is on sepsis – an acute, life-threatening condition affecting over 47 -50 million people…